Diferencia entre revisiones de «Dapsone»
(Remove disease-specific dosing covered by dynamic SMW tables) |
(Remove disease-specific entries now covered by AntibioticDose (5 sections)) |
||
| Línea 5: | Línea 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revisión actual - 11:08 20 mar 2026
Administration
- Type: Antibiotic
- Dosage Forms: 25,100
- Routes of Administration: Oral
Adult Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Bullous pemphigoid | 50mg PO QD; Use with topical or systemic corticosteroids | Bullous pemphigoid |
| Dermatitis herpetiformis | 50mg PO QD | Dermatitis herpetiformis |
| Leprosy | paucibacillary: 100mg PO QD x6mo; Use with rifampin; multibacillary: 100mg PO QD x12mo; Use with rifampin, clofazimine | Hansen's disease (leprosy) |
| Malaria | 100mg PO weekly | Suppression |
| Pneumocystis jirovecii pneumonia | 100mg PO once daily | Mild disease with TMP |
| Toxoplasmosis | 50mg PO QD; Off label use | Toxoplasmosis prophylaxis |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Pneumocystis jirovecii pneumonia | 2mg/kg/day PO (max 100mg) | Pediatric Mild |
| Pneumocystis jirovecii pneumonia | 2mg/kg/day PO daily (max 100mg) | Pediatric Prophylaxis alt |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Probably unsafe
Renal Dosing
- No adjustment
Hepatic Dosing
- Caution advised with hepatic impairment
- CBC qwk x4, qmo x6, then q6mo thereafter
- LFTs at baseline, then periodically
Contraindications
- Allergy to class/drug
- caution if renal or hepatic impairment
- caution if impaired cardiovascular function
Adverse Reactions
Serious
- anemia, hemolytic
- aplastic anemia
- agranulocytosis
- exfoliative dermatitis
- erythema multiforme
- toxic epidermal necrolysis
Common
Pharmacology
- Half-life: 28 hrs
- Metabolism: Liver, CYP450
- Excretion: Urine